Researchers from the Groupe de Recherche Action en Santé (GRAS) – a Center for Vaccine Development and Global Health (CVD) partner in Burkina Faso – confirmed TCVs are safe, immunogenic, and can be co-administered with routine-childhood immunizations at either
9-months or 15-months of age. In these studies, children received either TCV or a control vaccine in a randomized, double-blind study.

To build on these results, GRAS conducted a follow-up assessment 30-35 months after vaccination to compare immune responses in participants vaccinated with TCV versus control vaccine at the 15-month visit. The newly published study shows sustained vaccine immunogenicity and confirms co-administration of routine meningococcal conjugate vaccine does not diminish longer-term immune responses to TCV. These data mean Burkinabe children vaccinated at 15-months will likely have protection against typhoid until they reach school-age, at minimum. These data are important for decision-makers considering country-wide introduction of TCV.

The Typhoid Vaccine Acceleration Consortium (TyVAC), led by UMSOM’s CVD, works to address the burden of disease by accelerating the introduction of TCVs in high-risk countries.

Submitted by the Center for Vaccine Development and Global Health.